

CHAPTER ONE: INTRODUCTION.....	1
STUDY OBJECTIVES.....	1
REASONS FOR DOING THIS STUDY.....	1
INTENDED AUDIENCE.....	2
SCOPE OF THE STUDY.....	2
METHODOLOGY.....	2
INFORMATION SOURCES.....	2
ABOUT THE AUTHOR.....	3
RELATED BCC RESEARCH REPORTS.....	3
BCC ONLINE SERVICES.....	4
DISCLAIMER.....	4
 CHAPTER TWO: EXECUTIVE SUMMARY.....	 5
EXECUTIVE SUMMARY.....	5
<i>SUMMARY TABLE GLOBAL REVENUE OF HUMAN AND ANIMAL VACCINES, THROUGH 2015 (\$ MILLIONS)</i>	6
<i>SUMMARY FIGURE GLOBAL REVENUE OF HUMAN AND ANIMAL VACCINES, 2008-2015 (\$ MILLIONS)</i>	7
 CHAPTER THREE: OVERVIEW.....	 8
WHAT IS A VACCINE?.....	8
HISTORY OF VACCINES.....	8
<i>TABLE 1 HISTORY OF VACCINES, 1996-2006</i>	8
<i>TABLE 1 (CONTINUED)</i>	9
TYPES OF VACCINES.....	9
ATTENUATED (LIVE) VACCINES.....	9
Applications of Attenuated (Live) Vaccines.....	10
<i>TABLE 2 APPLICATIONS OF ATTENUATED (LIVE) VACCINES</i>	10
Advantages and Disadvantages of Attenuated (Live) Vaccines.....	10
<i>TABLE 3 ADVANTAGES AND DISADVANTAGES OF ATTENUATED (LIVE) VACCINES</i>	10
<i>TABLE 3 (CONTINUED)</i>	11
INACTIVATED (KILLED) VACCINES.....	11
Applications of Inactivated (Killed) Vaccines.....	11
<i>TABLE 4 APPLICATIONS OF INACTIVATED (KILLED) VACCINES</i>	11
<i>TABLE 4 (CONTINUED)</i>	12
Advantages and Disadvantages of Inactivated (Killed) Vaccines.....	12
<i>TABLE 5 ADVANTAGES AND DISADVANTAGES OF INACTIVED (KILLED) VACCINES</i>	12
TOXOID VACCINES.....	12
Applications of Toxoid Vaccines.....	13
<i>TABLE 6 APPLICATIONS OF TOXOID VACCINES</i>	13
Advantages and Disadvantages of Toxoid Vaccines.....	13

<i>TABLE 7 ADVANTAGES AND DISADVANTAGES OF TOXOID</i>	
<i>VACCINES</i>	13
SUBUNIT VACCINES.....	13
Applications of Subunit Vaccines.....	14
<i>TABLE 8 APPLICATIONS OF SUBUNIT VACCINES</i>	14
Advantages and Disadvantages of Subunit Vaccines	14
<i>TABLE 9 ADVANTAGES AND DISADVANTAGES OF SUBUNIT</i>	
<i>VACCINES</i>	14
CONJUGATE VACCINES.....	15
Applications of Conjugate Vaccines	15
<i>TABLE 10 APPLICATIONS OF CONJUGATE VACCINES</i>	15
Advantages and Disadvantages of Conjugate Vaccines.....	16
<i>TABLE 11 ADVANTAGES AND DISADVANTAGES OF CONJUGATE</i>	
<i>VACCINES</i>	16
RECOMBINANT VECTOR VACCINES.....	16
Applications of Recombinant Vector Vaccines	16
<i>TABLE 12 APPLICATIONS OF RECOMBINANT VECTOR VACCINES</i>	16
Advantages and Disadvantages of Recombinant Vector	
Vaccines	17
<i>TABLE 13 ADVANTAGES AND DISADVANTAGES OF RECOMBINANT</i>	
<i>VECTOR VACCINES</i>	17
DNA VACCINES.....	17
Applications of DNA Vaccines.....	18
<i>TABLE 14 APPLICATIONS OF DNA VACCINES</i>	18
Advantages and Disadvantages of DNA Vaccines	18
<i>TABLE 15 ADVANTAGES AND DISADVANTAGES OF DNA VACCINES</i>	18
INFECTIOUS DISEASES PREVENTABLE BY VACCINES	18
HUMAN DISEASES	19
Viral Diseases	19
<i>TABLE 16 VACCINE–PREVENTABLE HUMAN VIRAL DISEASES</i>	19
<i>TABLE 16 (CONTINUED)</i>	20
<i>TABLE 16 (CONTINUED)</i>	21
Bacterial Diseases	21
<i>TABLE 17 VACCINE–PREVENTABLE HUMAN BACTERIAL</i>	
<i>DISEASES</i>	21
<i>TABLE 17 (CONTINUED)</i>	22
<i>TABLE 17 (CONTINUED)</i>	23
ANIMAL DISEASES.....	23
<i>TABLE 18 VACCINE–PREVENTABLE ANIMAL DISEASES IN</i>	
<i>COMPANION ANIMALS</i>	24
<i>TABLE 18 (CONTINUED)</i>	25
<i>TABLE 19 VACCINE–PREVENTABLE ANIMAL DISEASES IN</i>	
<i>LIVESTOCK ANIMALS</i>	25
<i>TABLE 19 (CONTINUED)</i>	26

<i>TABLE 20 LIVESTOCK ANIMAL VACCINES</i>	26
<i>TABLE 20 (CONTINUED)</i>	27
<i>TABLE 20 (CONTINUED)</i>	28
<i>TABLE 20 (CONTINUED)</i>	29
<i>TABLE 20 (CONTINUED)</i>	30
<i>TABLE 20 (CONTINUED)</i>	31
<i>TABLE 20 (CONTINUED)</i>	32
<i>TABLE 20 (CONTINUED)</i>	33
<i>TABLE 20 (CONTINUED)</i>	34
CHAPTER FOUR: PREVALENCE.....	35
INCIDENCE AND IMMUNIZATION OF HUMAN DISEASES.....	35
REGIONAL DATA	35
<i>TABLE 21 REPORTED INCIDENCE DATA OF HUMAN DISEASES, BY</i> <i>REGION, 2007-2009</i>	35
<i>TABLE 21 (CONTINUED)</i>	36
<i>TABLE 22 IMMUNIZATION COVERAGE DATA OF HUMAN</i> <i>DISEASES, BY REGION, 2007-2009 (%)</i>	36
<i>TABLE 22 (CONTINUED)</i>	37
GLOBAL DATA.....	37
<i>TABLE 23 REPORTED CASES OF HUMAN DISEASES, 2007 AND 2008</i>	38
<i>TABLE 24 IMMUNIZATION COVERAGE OF HUMAN DISEASES (%)</i>	38
GLOBAL IMMUNIZATION UPTAKE DATA.....	38
<i>TABLE 25 UPTAKE OF NEW AND UNDERUSED VACCINES, 2008</i>	39
GLOBAL DEATHS DUE TO VACCINE–PREVENTABLE DISEASES.....	39
<i>TABLE 26 GLOBAL CHILD DEATHS DUE TO VACCINE–</i> <i>PREVENTABLE DISEASES, 2008</i>	40
CHAPTER FIVE: REGULATORY ASPECTS.....	41
<i>TABLE 27 REVISIONS TO EXISTING VACCINES, 2007-2010</i>	41
<i>TABLE 27 (CONTINUED)</i>	42
<i>TABLE 27 (CONTINUED)</i>	43
<i>TABLE 27 (CONTINUED)</i>	44
<i>TABLE 27 (CONTINUED)</i>	45
<i>TABLE 27 (CONTINUED)</i>	46
<i>TABLE 28 NEW VACCINES IN THE GLOBAL MARKET, 2007-2010</i>	47
<i>TABLE 28 (CONTINUED)</i>	48
<i>TABLE 28 (CONTINUED)</i>	49
<i>TABLE 28 (CONTINUED)</i>	50
<i>TABLE 28 (CONTINUED)</i>	51
CHAPTER SIX: INDUSTRY STRUCTURE.....	52
WHO–PREQUALIFIED VACCINE MANUFACTURERS/SUPPLIERS	52

<i>TABLE 29 WORLD HEALTH ORGANIZATION (WHO)–PREQUALIFIED MANUFACTURERS/SUPPLIERS OF HUMAN VACCINES, 2010</i>	52
<i>TABLE 29 (CONTINUED)</i>	53
<i>MANUFACTURERS/SUPPLIERS OF HUMAN VACCINES</i>	53
<i>ATTENUATED (LIVE) VACCINES</i>	53
<i>TABLE 30 LEADING MANUFACTURERS/SUPPLIERS OF ATTENUATED (LIVE) VACCINES</i>	53
<i>TABLE 30 (CONTINUED)</i>	54
<i>INACTIVATED (KILLED) VACCINES</i>	55
<i>TABLE 31 LEADING MANUFACTURERS/SUPPLIERS OF INACTIVATED (KILLED) VACCINES</i>	55
<i>CONJUGATE VACCINES</i>	56
<i>TABLE 32 LEADING MANUFACTURERS/SUPPLIERS OF CONJUGATE VACCINES</i>	56
<i>RECOMBINANT / RECOMBINANT DNA (RDNA) VACCINES</i>	56
<i>TABLE 33 LEADING MANUFACTURERS/SUPPLIERS OF RECOMBINANT/ RECOMBINANT DNA (RDNA) VACCINES</i>	56
<i>TABLE 33 (CONTINUED)</i>	57
<i>SUBUNIT VACCINES</i>	57
<i>TABLE 34 LEADING MANUFACTURERS/SUPPLIERS OF SUBUNIT VACCINES</i>	57
<i>TOXOID VACCINES</i>	57
<i>TABLE 35 LEADING MANUFACTURERS/SUPPLIERS OF TOXOID VACCINES</i>	57
<i>COMBINATION VACCINES</i>	58
<i>TABLE 36 LEADING MANUFACTURERS/SUPPLIERS OF COMBINATION VACCINES</i>	58
<i>MARKET SHARES OF INDUSTRY LEADERS OF HUMAN VACCINES</i>	59
<i>ATTENUATED (LIVE) VACCINES</i>	59
<i>TABLE 37 GLOBAL MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF ATTENUATED (LIVE) VACCINES, 2009 (%)</i>	59
<i>FIGURE 1 GLOBAL MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF ATTENUATED (LIVE) VACCINES, 2009 (%)</i>	60
<i>INACTIVATED (KILLED) VACCINES</i>	60
<i>TABLE 38 GLOBAL MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF INACTIVATED (KILLED) VACCINES, 2009 (%)</i>	61
<i>FIGURE 2 GLOBAL MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF INACTIVATED (KILLED) VACCINES, 2009 (%)</i>	61
<i>CONJUGATE VACCINES</i>	62

<i>TABLE 39 GLOBAL MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF CONJUGATE VACCINES, 2009 (%)</i>	62
<i>FIGURE 3 GLOBAL MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF CONJUGATE VACCINES, 2009 (%)</i>	63
RECOMBINANT/RECOMBINANT DNA (RDNA) VACCINES	63
<i>TABLE 40 GLOBAL MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF RECOMBINANT/RECOMBINANT DNA (RDNA) VACCINES, 2009 (%)</i>	64
<i>FIGURE 4 GLOBAL MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF RECOMBINANT/RECOMBINANT DNA (RDNA) VACCINES, 2009 (%)</i>	64
SUBUNIT VACCINES.....	65
<i>TABLE 41 GLOBAL MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF SUBUNIT VACCINES, 2009 (%)</i>	65
<i>FIGURE 5 GLOBAL MARKET SHARES OF MANUFACTURERS/ SUPPLIERS OF SUBUNIT VACCINES, 2009 (%)</i>	65
TOXOID VACCINES	66
<i>TABLE 42 GLOBAL MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF TOXOID VACCINES, 2009 (%)</i>	66
<i>FIGURE 6 GLOBAL MARKET SHARES OF MANUFACTURERS/ SUPPLIERS OF TOXOID VACCINES, 2009 (%)</i>	66
COMBINATION VACCINES	67
<i>TABLE 43 GLOBAL MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF COMBINATION VACCINES, 2009 (%)</i>	67
<i>FIGURE 7 GLOBAL MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF COMBINATION VACCINES, 2009 (%)</i>	67
CHAPTER SEVEN: NEW DEVELOPMENTS.....	68
NEW DEVELOPMENTS.....	68
<i>TABLE 44 NEW DEVELOPMENTS IN THE RESEARCH PIPELINE OF HUMAN VACCINES (AS OF AUGUST 2010)</i>	69
<i>TABLE 44 (CONTINUED)</i>	70
<i>TABLE 44 (CONTINUED)</i>	71
<i>TABLE 44 (CONTINUED)</i>	72
<i>TABLE 44 (CONTINUED)</i>	73
<i>TABLE 44 (CONTINUED)</i>	74
CHAPTER EIGHT: MARKET ANALYSIS: HUMAN	75

<i>TABLE 45 GLOBAL MARKET FOR HUMAN VACCINES BY REGION, THROUGH 2015 (\$ MILLIONS)</i>	75
<i>FIGURE 8 GLOBAL MARKET FOR HUMAN VACCINES BY REGION, 2008-2015 (\$ MILLIONS)</i>	76
ATTENUATED (LIVE) VACCINES	76
MARKET OVERVIEW	77
MARKET REVENUE.....	78
<i>TABLE 46 GLOBAL MARKET FOR ATTENUATED (LIVE) VACCINES, BY REGION, THROUGH 2015 (\$ MILLIONS)</i>	78
<i>FIGURE 9 GLOBAL MARKET FOR ATTENUATED (LIVE) VACCINES, BY REGION, 2008-2015 (\$ MILLIONS)</i>	79
INACTIVATED (KILLED) VACCINES	79
MARKET OVERVIEW	80
MARKET REVENUE.....	81
<i>TABLE 47 GLOBAL MARKET FOR INACTIVATED (KILLED) VACCINES, THROUGH 2015 (\$ MILLIONS)</i>	81
<i>FIGURE 10 GLOBAL MARKET FOR INACTIVATED (KILLED) VACCINES, 2008-2015 (\$ MILLIONS)</i>	81
CONJUGATE VACCINES	82
MARKET OVERVIEW	82
MARKET REVENUE.....	83
<i>TABLE 48 GLOBAL MARKET FOR CONJUGATE VACCINES, THROUGH 2015 (\$ MILLIONS)</i>	83
<i>FIGURE 11 GLOBAL MARKET FOR CONJUGATE VACCINES, 2008-2015 (\$ MILLIONS)</i>	84
RECOMBINANT/RECOMBINANT DNA (RDNA) VACCINES	84
MARKET OVERVIEW	84
MARKET REVENUE.....	85
<i>TABLE 49 GLOBAL MARKET FOR RECOMBINANT/RECOMBINANT DNA (RDNA) VACCINES, THROUGH 2015 (\$ MILLIONS)</i>	86
<i>FIGURE 12 GLOBAL MARKET FOR RECOMBINANT/RECOMBINANT DNA (RDNA) VACCINES, 2008-2015 (\$ MILLIONS)</i>	86
SUBUNIT VACCINES	87
MARKET OVERVIEW	87
MARKET REVENUE.....	88
<i>TABLE 50 GLOBAL MARKET FOR SUBUNIT VACCINES, THROUGH 2015 (\$ MILLIONS)</i>	88
<i>FIGURE 13 GLOBAL MARKET FOR SUBUNIT VACCINES, 2008-2015 (\$ MILLIONS)</i>	89
TOXOID VACCINES	89
MARKET OVERVIEW	90
MARKET REVENUE.....	91
<i>TABLE 51 GLOBAL MARKET FOR TOXOID VACCINES, THROUGH 2015 (\$ MILLIONS)</i>	91

<i>FIGURE 14 GLOBAL MARKET FOR TOXOID VACCINES, 2008-2015 (\$ MILLIONS)</i>	91
COMBINATION VACCINES	92
MARKET OVERVIEW	92
MARKET REVENUE.....	93
<i>TABLE 52 GLOBAL MARKET FOR COMBINATION VACCINES, BY REGION THROUGH 2015 (\$ MILLIONS)</i>	93
<i>FIGURE 15 GLOBAL MARKET FOR COMBINATION VACCINES, BY REGION, 2008-2015 (\$ MILLIONS)</i>	94
MARKET SHARES OF HUMAN VACCINES, BY REGION	94
<i>TABLE 53 GLOBAL HUMAN VACCINES MARKET SHARES BY REGION, 2009 (%)</i>	95
<i>FIGURE 16 GLOBAL HUMAN VACCINES MARKET SHARES BY REGION, 2009 (%)</i>	95
MARKET SHARES OF HUMAN VACCINES, BY TYPE.....	95
<i>TABLE 54 GLOBAL HUMAN VACCINES MARKET SHARES BY VACCINE TYPE, 2009 (%)</i>	96
<i>FIGURE 17 GLOBAL HUMAN VACCINES MARKET SHARES BY VACCINE TYPE, 2009 (%)</i>	96
CHAPTER NINE: ANIMAL HEALTH MARKET	97
INDUSTRY MANUFACTURERS OF ANIMAL HEALTH PRODUCTS	97
MARKET OVERVIEW	98
MARKET REVENUE.....	99
<i>TABLE 55 GLOBAL ANIMAL HEALTH REVENUES BY MARKET LEADERS, 2008-2010 (\$ MILLIONS)</i>	99
<i>TABLE 56 GLOBAL ANIMAL HEALTH MARKET SHARES BY REVENUE, 2009 (%)</i>	99
<i>FIGURE 18 GLOBAL ANIMAL HEALTH MARKET SHARES BY REVENUE, 2009 (%)</i>	100
ANIMAL VACCINES.....	100
<i>TABLE 57 GLOBAL MARKET FOR ANIMAL VACCINES, THROUGH 2015 (\$ MILLIONS)</i>	101
<i>FIGURE 19 GLOBAL MARKET FOR ANIMAL VACCINES, 2008-2015 (\$ MILLIONS)</i>	102
CHAPTER TEN: MARKET BY APPLICATIONS – HUMANS.....	103
<i>TABLE 58 DISEASES AND INFECTIONS WITH DEVELOPED HUMAN VACCINES BASED ON MICROORGANISM</i>	103
<i>TABLE 59 DISEASES AND INFECTIONS WITH DEVELOPED HUMAN VACCINES BASED ON TREATMENT</i>	104
MENINGOCOCCAL/PNEUMOCOCCAL DISEASES	105
MARKET REVENUE.....	105

<i>TABLE 60 GLOBAL SALES OF HUMAN VACCINES IN MENINGOCOCCAL/ PNEUMOCOCCAL DISEASES MARKET, THROUGH 2015 (\$ MILLIONS)</i>	106
<i>FIGURE 20 GLOBAL SALES OF HUMAN VACCINES IN MENINGOCOCCAL/ PNEUMOCOCCAL DISEASES MARKET, 2008-2015 (\$ MILLIONS)</i>	106
<i>TABLE 61 TOP-SELLING GROUPS OF MENINGOCOCCAL/ PNEUMOCOCCAL VACCINES FOR 2009 BY MARKET SHARE (%)</i>	107
<i>INFLUENZA (SEASONAL AND PANDEMIC) DISEASES</i>	107
<i>MARKET REVENUE</i>	108
<i>TABLE 62 GLOBAL SALES OF HUMAN VACCINES IN INFLUENZA DISEASES MARKET, THROUGH 2015 (\$ MILLIONS)</i>	109
<i>FIGURE 21 GLOBAL SALES OF HUMAN VACCINES IN INFLUENZA DISEASES MARKET, 2008-2015 (\$ MILLIONS)</i>	109
<i>TABLE 63 TOP-SELLING GROUPS OF INFLUENZA VACCINES BY MARKET SHARE, 2009 (%)</i>	110
<i>PEDIATRIC/POLIO/PERTUSSIS/HIB DISEASES</i>	110
<i>MARKET REVENUE</i>	111
<i>TABLE 64 GLOBAL SALES OF HUMAN VACCINES IN PEDIATRIC/POLIO/ PERTUSSIS/HIB DISEASES MARKET, THROUGH 2015 (\$ MILLIONS)</i>	112
<i>FIGURE 22 GLOBAL SALES OF HUMAN VACCINES IN PEDIATRIC/ POLIO/PERTUSSIS/HIB DISEASES MARKET, 2008-2015 (\$ MILLIONS)</i>	112
<i>TABLE 65 TOP-SELLING GROUPS OF PEDIATRIC/POLIO/PERTUSSIS/HIB VACCINES BY MARKET SHARE, 2009 (%)</i>	113
<i>ADULT/ADOLESCENT BOOSTER RELATED DISEASES</i>	113
<i>MARKET REVENUE</i>	113
<i>TABLE 66 GLOBAL SALES OF HUMAN VACCINES IN ADULT/ADOLESCENT BOOSTER-RELATED DISEASES MARKET, THROUGH 2015 (\$ MILLIONS)</i>	114
<i>FIGURE 23 GLOBAL SALES OF HUMAN VACCINES IN ADULT/ADOLESCENT BOOSTER-RELATED DISEASES MARKET, 2008-2015 (\$ MILLIONS)</i>	114
<i>TABLE 67 TOP-SELLING GROUPS OF ADULT/ADOLESCENT BOOSTER-RELATED VACCINES BY MARKET SHARE, 2009 (%)</i>	115
<i>TRAVEL AND OTHER ENDEMIC DISEASES</i>	115
<i>MARKET REVENUE</i>	116
<i>TABLE 68 GLOBAL SALES OF HUMAN VACCINES IN TRAVEL AND OTHER ENDEMIC DISEASES MARKET, THROUGH 2015 (\$ MILLIONS)</i>	117
<i>FIGURE 24 GLOBAL SALES OF HUMAN VACCINES IN TRAVEL AND OTHER ENDEMIC DISEASES MARKET, 2008- 2015 (\$ MILLIONS)</i>	117

<i>TABLE 69 TOP-SELLING GROUPS OF TRAVEL AND OTHER ENDEMIC VACCINES BY MARKET SHARE, 2009 (%)</i>	118
HPV DISEASE.....	118
MARKET REVENUE.....	119
<i>TABLE 70 GLOBAL SALES OF HUMAN VACCINES IN HPV DISEASE MARKET, THROUGH 2015 (\$ MILLIONS)</i>	119
<i>FIGURE 25 GLOBAL SALES OF HUMAN VACCINES IN HPV DISEASE MARKET, 2008-2015 (\$ MILLIONS)</i>	120
<i>TABLE 71 TOP-SELLING HPV VACCINES IN THE ORDER OF THEIR SALES, 2009 (%)</i>	120
ROTAVIRUS DISEASE.....	121
MARKET REVENUE.....	121
<i>TABLE 72 GLOBAL SALES OF HUMAN VACCINES IN ROTAVIRUS DISEASE MARKET, THROUGH 2015 (\$ MILLIONS)</i>	121
<i>FIGURE 26 GLOBAL SALES OF HUMAN VACCINES IN ROTAVIRUS DISEASE MARKET, 2008-2015 (\$ MILLIONS)</i>	122
<i>TABLE 73 TOP-SELLING ROTAVIRUS VACCINES BY MARKET SHARE, 2009 (%)</i>	122
OTHER DISEASES.....	123
MARKET REVENUE.....	124
<i>TABLE 74 GLOBAL SALES OF HUMAN VACCINES IN OTHER DISEASES MARKET, THROUGH 2015 (\$ MILLIONS)</i>	124
<i>FIGURE 27 GLOBAL SALES OF HUMAN VACCINES IN OTHER DISEASES MARKET, 2008-2015 (\$ MILLIONS)</i>	125
<i>TABLE 75 TOP-SELLING OTHER VACCINES FOR 2009 BY MARKET SHARE (%)</i>	125
MARKET SHARE OF APPLICATIONS.....	126
<i>TABLE 76 SHARE OF VARIOUS CATEGORIES OF VACCINES IN THE HUMAN VACCINES MARKET, 2009 (%)</i>	126
<i>FIGURE 28 SHARE OF VARIOUS CATEGORIES OF VACCINES IN THE HUMAN VACCINES MARKET, 2009 (%)</i>	127
CHAPTER ELEVEN: PATENT ANALYSIS.....	128
TOTAL NUMBER OF PATENTS.....	128
<i>TABLE 77 NUMBER OF SIGNIFICANT PATENTS, 2006 TO SEPTEMBER 2010</i>	129
<i>FIGURE 29 NUMBER OF SIGNIFICANT PATENTS, 2006 TO SEPTEMBER 2010</i>	129
<i>FIGURE 30 PERCENT OF SIGNIFICANT PATENTS, 2006 TO SEPTEMBER 2010 (%)</i>	130
PATENTS BY TYPE AND YEAR.....	130
<i>TABLE 78 PATENTS BY TECHNOLOGY, 2006 TO SEPTEMBER 2010</i>	131
<i>FIGURE 31 PATENTS BY TECHNOLOGY, 2006 TO SEPTEMBER 2010</i>	131
PATENTS BY COMPANY.....	132
INACTIVATED (KILLED) VACCINE TECHNOLOGY.....	132

<i>TABLE 79 NUMBER OF U.S. PATENTS BY COMPANY UTILIZING INACTIVATED (KILLED) VACCINE TECHNOLOGY, 2006 TO SEPTEMBER 2010</i>	132
<i>FIGURE 32 NUMBER OF U.S. PATENTS BY COMPANY UTILIZING INACTIVATED (KILLED) VACCINE TECHNOLOGY, 2006 TO SEPTEMBER 2010</i>	133
<i>ATTENUATED (LIVE) VACCINE TECHNOLOGY</i>	133
<i>TABLE 80 NUMBER OF U.S. PATENTS BY COMPANY UTILIZING ATTENUATED (LIVE) VACCINE TECHNOLOGY, 2006 TO SEPTEMBER 2010</i>	134
<i>FIGURE 33 NUMBER OF U.S. PATENTS BY COMPANY UTILIZING ATTENUATED (LIVE) VACCINE TECHNOLOGY, 2006 TO SEPTEMBER 2010</i>	135
<i>CONJUGATE VACCINE TECHNOLOGY</i>	135
<i>TABLE 81 NUMBER OF U.S. PATENTS BY COMPANY UTILIZING CONJUGATE VACCINE TECHNOLOGY, 2006 TO SEPTEMBER 2010</i>	136
<i>FIGURE 34 NUMBER OF U.S. PATENTS BY COMPANY UTILIZING CONJUGATE VACCINE TECHNOLOGY, 2006 TO SEPTEMBER 2010</i>	136
<i>TOXOID VACCINE TECHNOLOGY</i>	137
<i>TABLE 82 NUMBER OF U.S. PATENTS BY COMPANY UTILIZING TOXOID VACCINE TECHNOLOGY, 2006 TO SEPTEMBER 2010</i>	137
<i>FIGURE 35 NUMBER OF U.S. PATENTS BY COMPANY UTILIZING TOXOID VACCINE TECHNOLOGY, 2006 TO SEPTEMBER 2010</i>	137
<i>RECOMBINANT/RDNA VACCINE TECHNOLOGY</i>	138
<i>TABLE 83 NUMBER OF U.S. PATENTS BY COMPANY UTILIZING RECOMBINANT/RDNA VACCINE TECHNOLOGY, 2006 TO SEPTEMBER 2010</i>	138
<i>TABLE 83 (CONTINUED)</i>	139
<i>FIGURE 36 NUMBER OF U.S. PATENTS BY COMPANY UTILIZING RECOMBINANT/RDNA VACCINE TECHNOLOGY, 2006 TO SEPTEMBER 2010</i>	139
<i>SUBUNIT VACCINE TECHNOLOGY</i>	140
<i>TABLE 84 NUMBER OF U.S. PATENTS BY COMPANY UTILIZING SUBUNIT VACCINE TECHNOLOGY, 2006 TO SEPTEMBER 2010</i>	140
<i>FIGURE 37 NUMBER OF U.S. PATENTS BY COMPANY UTILIZING SUBUNIT VACCINE TECHNOLOGY, 2006 TO SEPTEMBER 2010</i>	140
<i>OTHER/COMBINED VACCINE TECHNOLOGY</i>	141
<i>TABLE 85 NUMBER OF U.S. PATENTS BY COMPANY UTILIZING OTHER/COMBINED VACCINE TECHNOLOGY, 2006 TO SEPTEMBER 2010</i>	141
<i>TABLE 85 (CONTINUED)</i>	142

<i>FIGURE 38 NUMBER OF U.S. PATENTS BY COMPANY UTILIZING OTHER/ COMBINED VACCINE TECHNOLOGY, 2006 TO SEPTEMBER 2010</i>	143
<i>PATENTS BY COUNTRY</i>	143
<i>INACTIVATED (KILLED) VACCINE TECHNOLOGY</i>	143
<i>TABLE 86 NUMBER OF U.S. PATENTS BY COUNTRY UTILIZING INACTIVATED (KILLED) VACCINE TECHNOLOGY, 2006 TO SEPTEMBER 2010</i>	144
<i>FIGURE 39 NUMBER OF U.S. PATENTS BY COUNTRY UTILIZING INACTIVATED (KILLED) VACCINE TECHNOLOGY, 2006 TO SEPTEMBER 2010</i>	145
<i>ATTENUATED (LIVE) VACCINE TECHNOLOGY</i>	145
<i>TABLE 87 NUMBER OF U.S. PATENTS BY COUNTRY UTILIZING ATTENUATED (LIVE) VACCINE TECHNOLOGY, 2006 TO SEPTEMBER 2010</i>	145
<i>TABLE 87 (CONTINUED)</i>	146
<i>FIGURE 40 NUMBER OF U.S. PATENTS BY COUNTRY UTILIZING ATTENUATED (LIVE) VACCINE TECHNOLOGY, 2006–2010</i>	146
<i>CONJUGATE VACCINE TECHNOLOGY</i>	147
<i>TABLE 88 NUMBER OF U.S. PATENTS BY COUNTRY UTILIZING CONJUGATE VACCINE TECHNOLOGY, 2006 TO SEPTEMBER 2010</i>	147
<i>FIGURE 41 NUMBER OF U.S. PATENTS BY COUNTRY UTILIZING CONJUGATE VACCINE TECHNOLOGY, 2006 TO SEPTEMBER 2010</i>	148
<i>TABLE 89 NUMBER OF U.S. PATENTS BY COUNTRY UTILIZING TOXOID VACCINE TECHNOLOGY, 2006 TO SEPTEMBER 2010</i>	148
<i>FIGURE 42 NUMBER OF U.S. PATENTS BY COUNTRY UTILIZING TOXOID VACCINE TECHNOLOGY, 2006 TO SEPTEMBER 2010</i>	149
<i>RECOMBINANT/ DNA/ RDNA VACCINE TECHNOLOGY</i>	149
<i>TABLE 90 NUMBER OF U.S. PATENTS BY COUNTRY UTILIZING RECOMBINANT/DNA/RDNA VACCINE TECHNOLOGY, 2006 TO SEPTEMBER 2010</i>	150
<i>FIGURE 43 NUMBER OF U.S. PATENTS BY COUNTRY UTILIZING RECOMBINANT/DNA/RDNA VACCINE TECHNOLOGY, 2006 TO SEPTEMBER 2010</i>	151
<i>SUBUNIT VACCINE TECHNOLOGY</i>	151
<i>TABLE 91 NUMBER OF U.S. PATENTS BY COUNTRY UTILIZING SUBUNIT VACCINE TECHNOLOGY, 2006 TO SEPTEMBER 2010</i>	152
<i>FIGURE 44 NUMBER OF U.S. PATENTS BY COUNTRY UTILIZING SUBUNIT VACCINE TECHNOLOGY, 2006 TO SEPTEMBER 2010</i>	152
<i>OTHER/COMBINED VACCINE TECHNOLOGY</i>	152

<i>TABLE 92 NUMBER OF U.S. PATENTS BY COUNTRY UTILIZING OTHER/COMBINED VACCINE TECHNOLOGY, 2006 TO SEPTEMBER 2010</i>	153
<i>FIGURE 45 NUMBER OF U.S. PATENTS BY COUNTRY UTILIZING OTHER/COMBINED VACCINE TECHNOLOGY, 2006 TO SEPTEMBER 2010</i>	154
<i>TABLE 93 NUMBER OF U.S. PATENTS BY COUNTRY FOR ALL VACCINE TYPES, 2006 TO SEPTEMBER 2010 (%)</i>	154
<i>TABLE 93 (CONTINUED)</i>	155
<i>FIGURE 46 PATENT SHARES BY COUNTRY FOR VACCINES, 2006 TO SEPTEMBER 2010 (%)</i>	156
<i>PATENTS BY ASSIGNEE</i>	157
<i>INACTIVATED (KILLED) VACCINE TECHNOLOGY</i>	157
<i>TABLE 94 PATENTS BY ASSIGNEE UTILIZING INACTIVATED (KILLED) VACCINE TECHNOLOGY, 2006 TO SEPTEMBER 2010</i>	157
<i>FIGURE 47 PATENTS BY ASSIGNEE UTILIZING INACTIVATED (KILLED) VACCINE TECHNOLOGY, 2006 TO SEPTEMBER 2010</i>	157
<i>ATTENUATED (LIVE) VACCINE TECHNOLOGY</i>	158
<i>TABLE 95 PATENTS BY ASSIGNEE UTILIZING ATTENUATED (LIVE) VACCINE TECHNOLOGY, 2006 THROUGH SEPTEMBER 2010</i>	158
<i>FIGURE 48 PATENTS BY ASSIGNEE UTILIZING ATTENUATED (LIVE) VACCINE TECHNOLOGY, 2006 TO SEPTEMBER 2010</i>	158
<i>CONJUGATE VACCINE TECHNOLOGY</i>	159
<i>TABLE 96 PATENTS BY ASSIGNEE UTILIZING CONJUGATE VACCINE TECHNOLOGY, 2006 TO SEPTEMBER 2010</i>	159
<i>FIGURE 49 PATENTS BY ASSIGNEE UTILIZING CONJUGATE VACCINE TECHNOLOGY, 2006 TO SEPTEMBER 2010</i>	159
<i>TOXOID VACCINE TECHNOLOGY</i>	160
<i>TABLE 97 PATENTS BY ASSIGNEE UTILIZING TOXOID VACCINE TECHNOLOGY, 2006 TO SEPTEMBER 2010</i>	160
<i>FIGURE 50 PATENTS BY ASSIGNEE UTILIZING TOXOID VACCINE TECHNOLOGY, 2006 TO SEPTEMBER 2010</i>	160
<i>RECOMBINANT/RDNA VACCINE TECHNOLOGY</i>	161
<i>TABLE 98 PATENTS BY ASSIGNEE UTILIZING RECOMBINANT/RDNA VACCINE TECHNOLOGY, 2006 TO SEPTEMBER 2010</i>	161
<i>FIGURE 51 PATENTS BY ASSIGNEE UTILIZING RECOMBINANT/RDNA VACCINE TECHNOLOGY, 2006 TO SEPTEMBER 2010</i>	161
<i>SUBUNIT VACCINE TECHNOLOGY</i>	162
<i>TABLE 99 PATENTS BY ASSIGNEE UTILIZING SUBUNIT VACCINE TECHNOLOGY, 2006 TO SEPTEMBER 2010</i>	162

<i>FIGURE 52 PATENTS BY ASSIGNEE UTILIZING SUBUNIT VACCINE TECHNOLOGY, 2006 TO SEPTEMBER 2010</i>	162
OTHER/COMBINED VACCINE TECHNOLOGY	163
<i>TABLE 100 PATENTS BY ASSIGNEE UTILIZING OTHER/COMBINED VACCINE TECHNOLOGY, 2006 TO SEPTEMBER 2010</i>	163
<i>FIGURE 53 PATENTS BY ASSIGNEE UTILIZING OTHER/COMBINED VACCINE TECHNOLOGY, 2006 TO SEPTEMBER 2010</i>	163
CHAPTER TWELVE: CURRENT SITUATION OF THE GLOBAL VACCINES MARKET	164
FACTS ABOUT THE GLOBAL VACCINES MARKET	164
FACTORS AFFECTING THE SALES OF VACCINES	165
COMPETITION.....	165
COST.....	165
TRENDS	166
IMMUNIZATION FUNDING	166
GLOBAL IMMUNIZATION VISION AND STRATEGY (GIVS)	166
<i>TABLE 101 AIMS OF GIVS</i>	167
<i>TABLE 102 GOALS OF GIVS</i>	167
<i>TABLE 103 STRATEGIES OF GIVS</i>	168
CURRENT SITUATION	168
<i>TABLE 104 GLOBAL FUNDING GAP BY REGION FOR IMMUNIZATION WORK, 2010-2011 (\$ MILLIONS)</i>	169
VACCINE PREVENTABLE DISEASES UPDATE.....	169
CURRENT VACCINE PRIORITIZATION.....	169
<i>TABLE 105 VACCINE PRIORITIZATION, 2009-2010</i>	170
CURRENT AND FUTURE (PROPOSED) VACCINE MILESTONES	171
<i>TABLE 106 VACCINE MILESTONES 2009-2012</i>	171
INFLUENZA VIRUS VACCINES UPDATE FOR THE 2010 THROUGH 2011 SEASON.....	172
<i>TABLE 107 INFLUENZA VACCINES FOR THE 2010-2011 SEASON</i>	172
CHAPTER THIRTEEN: COMPANY PROFILES	173
ADVAXIS.....	173
BAYER ANIMAL HEALTH	173
BUL BIO – NATIONAL CENTER OF INFECTIOUS AND PARASITIC DISEASES LTD. (BB-NCIPD LTD.).....	174
BHARAT BIOTECH	174
BIO FARMA	175
BIOLOGICAL E. LIMITED.....	176
BIO-MANGUINHOS.....	176
BIOPROPERTIES.....	177

BOEHRINGER INGELHEIM VETMEDICA, INC.	177
CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY.....	178
CEVA SANTE ANIMALE.....	179
COLORADO SERUM COMPANY	179
CRUCELL	180
CSL LTD.....	180
ELI LILLY & CO.....	181
EMERGENT BIOSOLUTIONS.....	182
FATRO.....	182
GLAXOSMITHKLINE.....	183
GREEN CROSS.....	184
HAFFKINE BIO-PHARMACEUTICAL CORPORATION LTD.	184
INDOVAX.....	185
INSTITUT PASTEUR DE DAKAR.....	185
INTERCELL.....	186
JAPAN BCG LABORATORY	186
KING PHARMACEUTICALS INC.	187
LOHMANN INTERNATIONAL.....	188
MEDIMMUNE	188
MERCK & CO., INC.	189
NIPPON BIOLOGICALS, INC.....	190
NOVARTIS AG	190
PANACEA BIOTEC.....	191
PFIZER INC.....	192
ROMVAC	193
SANOFI-AVENTIS (SANOFI PASTEUR).....	193
SERUM INSTITUTE OF INDIA LTD.	194
STATENS SERUM INSTITUT	195
THE RESEARCH FOUNDATION FOR MICROBIAL DISEASES OF OSAKA UNIVERSITY	196
VENTRI BIOLOGICALS.....	196
ZYDUS CADILA	197
APPENDIX I.....	198
ABBREVIATIONS	198
ABBREVIATIONS (CONTINUED).....	199